Cost analysis of drugs used in management of heart failure with reduced ejection fraction and marketed in India
DOI:
https://doi.org/10.18203/2319-2003.ijbcp20242417Keywords:
Cost Analysis, Cost Variation, Cost ratio, HFrEFAbstract
Background: Heart failure is characterised by significant morbidity, mortality, poor functional capacity, reduced quality of life, and high cost of lifelong medications. No studies have been performed yet on cost analysis of oral drugs used in management of HFrEF (Heart Failure with Reduced Ejection Fraction). So, we analysed cost variations of different brands of such drugs which are marketed in India.
Methods: It was an analytical study in which maximum and minimum costs in rupees per 10 tablets/capsules of each drug in same strength, manufactured by different pharmaceutical companies in India, were obtained from “Current Index of Medical Specialties” (CIMS) January to April 2023, Indian Drug Review (IDR 2023) and Drug Today (January– April 2023 Cost ratio and % cost variation were calculated for each drug. % Cost variation= Maximum cost- Minimum cost × 100/ Minimum cost. Cost ratio= Price of the costliest brand/ Price of the least costly brand.
Results: Totally 652 brands of HFrEF management drugs from different classes were evaluated. Telmisartan 80 mg had highest cost ratio of 44 and 4300% cost variation, while Spironolactone 25 mg had lowest cost ratio of 1.29 and 31.11% cost variation.
Conclusions: Our study showed significant cost variation in different brands of the same drugs that are used in the management of HFrEF. To lessen economic burden and to improve adherence to treatment, also considering the demographics, it is desirable for doctors to prescribe least costly brands/ generic drugs, to meet the health-care needs of such patients.
Metrics
References
Murphy SP, Ibrahim NE, Januzzi JL. Heart failure with reduced ejection fraction: a review. Jama. 2020;324(5):488-504.
Haydock PM, Flett AS. Management of heart failure with reduced ejection fraction. Heart. 2022;108(19):1571-9.
Savarese G, Becher PM, Lund LH, Seferovic P, Rosano GM, Coats AJ. Global burden of heart failure: a comprehensive and updated review of epidemiology. Cardiovascular research. 2022;118(17):3272-87.
Census of India Website: Office of the Registrar General and Census Commissioner, India. Available at: censusindia.gov.in. Accessed on 28th March 2024.
Guha S, Harikrishnan S, Ray S, Sethi R, Ramakrishnan S, Banerjee S, Bahl VK, Goswami KC, Banerjee AK, Shanmugasundaram S, Kerkar PG. CSI position statement on management of heart failure in India. IHJ. 2018;70(1):1.
Pillai HS, Ganapathi S. Heart failure in South Asia. Curr Cardiol Rev. 2013;9:102-111.
Chaturvedi V, Parakh N, Seth S, Bhargava B, Ramakrishnan S, Roy A, et al. heart failure in India: The INDUS (INDia Ukieri Study). JPCS. 2016;2:28-35.
Harikrishnan S, Sanjay G, Agarwal A. One-year mortality outcomes and hospital readmissions of patients admitted with acute heart failure: data from the Trivandrum Heart Failure Registry in Kerala, India. Am Heart J. 2017;189:193-99.
Chavey WE, Hogikyan RV, Van Harrison R, Nicklas JM. Heart failure due to reduced ejection fraction: medical management. American Family Physician. 2017;95(1):13-20.
Asaria M, Mazumdar S, Chowdhury S, Mazumdar P, Mukhopadhyay A, Gupta I. Socioeconomic inequality in life expectancy in India. BMJ Global Health. 2019;4(3):1445.
Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, Deswal A, Drazner MH, Dunlay SM, Evers LR, Fang JC. 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2022;79(17):263-421.
Yan BW, Spahillari A, Pandya A. Cost-effectiveness of quadruple therapy in management of heart failure with reduced ejection fraction in the united states. circulation: cardiovascular quality and outcomes. 2023;16(6):9793.
Urbich M, Globe G, Pantiri K, Heisen M, Bennison C, Wirtz HS, Di Tanna GL. A systematic review of medical costs associated with heart failure in the USA (2014–2020). Pharmacoeconomics. 2020;38:1219-36.
Singh A, Chauhan S, Devasia T, Karkala YR, Paramasivam G, Shetty PN, Uppunda D, Kareem H. Financial burden of heart failure in a developing country: cost analysis from Manipal Heart Failure Registry, India. JPH. 2021;29:585-94.
Mishra S, Mohan JC, Nair T, Chopra VK, Harikrishnan S, Guha S, et al. Management protocols for chronic heart failure in India. IHJ. 2018;70(1):105-27.
Ray A, Najmi A, Khandelwal G, Sadasivam B. A cost variation analysis of drugs available in the Indian market for the management of thromboembolic disorders. Cureus. 2020;12(5).
Mulakaluri PP: Generic medicines in the Indian scenario - what are we expecting? Telangana J Psychiatr. 2017;3:1-3.